NAMS in the 13F filings
Newamsterdam Pharma Company · CUSIP N62509109
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 2 Sep 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 6 listed it in both
- Shares listed
- 39,453,037
- combined, among listed positions
- Reported value
- $1.3bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 21 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,259,118.
Managers listing NAMS in Q2 2026
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 10,339,663 shares now+1,573,852
- T. Rowe Price Associates Incnew position · 1,167,357 shares now+1,167,357
- Capital World Investorsexisting position · 12,230,557 shares now+1,121,523
- Maverick Capital Ltdexisting position · 3,267,802 shares now+1,081,400
- Susquehanna International Group LLPexisting position · 754,327 shares now+736,502
Reductions
- Wellington Management Group LLPexisting position · 218,749 shares now-4,897,069
- Citadel Advisors LLCexisting position · 645,805 shares now-66,259
- Brevan Howard Capital Management LPexisting position · 9,548 shares now-7,252
- Invesco Ltdexisting position · 6,617 shares now-674
New positions and exits
New (9)
Exited (2)
- Marshall Wace LLPwas $8.5m
- Freestone Grove Partners LPwas $96k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2022 | 1 | $39m | n.a. | n.a. |
| Q1 2023 | 1 | $53m | n.a. | n.a. |
| Q2 2023 | 1 | $78m | n.a. | n.a. |
| Q3 2023 | 1 | $74m | n.a. | n.a. |
| Q4 2023 | 1 | $90m | 0 | 0 |
| Q1 2024 | 1 | $190m | 0 | 0 |
| Q2 2024 | 2 | $163m | 1 | 0 |
| Q3 2024 | 2 | $153m | 1 | 0 |
| Q4 2024 | 5 | $322m | 4 | 1 |
| Q1 2025 | 5 | $391m | 4 | 0 |
| Q2 2025 | 5 | $376m | 2 | 2 |
| Q3 2025 | 5 | $599m | 2 | 3 |
| Q4 2025 | 8 | $851m | 17 | 5 |
| Q1 2026 | 6 | $820m | 13 | 11 |
| Q2 2026 | 6 | $790m | 21 | 6 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
NAMS and LLY →NAMS and JNJ →NAMS and VRTX →Choose a stock to compare with NAMS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own NAMS, latest filings →Back to the 13F Explorer →